JP2013532725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532725A5 JP2013532725A5 JP2013523129A JP2013523129A JP2013532725A5 JP 2013532725 A5 JP2013532725 A5 JP 2013532725A5 JP 2013523129 A JP2013523129 A JP 2013523129A JP 2013523129 A JP2013523129 A JP 2013523129A JP 2013532725 A5 JP2013532725 A5 JP 2013532725A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- methyl
- interferon
- pyrrolidinyl
- additional compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- -1 7-((2-((2S, 5S) -1-((2S) -2- (4,4-difluorocyclohexyl) -2-((methoxy Carbonyl) amino) acetyl) -5-methyl-2-pyrrolidinyl) -1H-benzimidazol-5-yl) ethynyl) -1H-naphtho [1,2-d] imidazol-2-yl Chemical group 0.000 claims 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102100008763 IFNA2 Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 229960000329 Ribavirin Drugs 0.000 claims 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 101710036216 ATEG_03556 Proteins 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 Amantadine Drugs 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 101700022936 IFNA2 Proteins 0.000 claims 2
- 101710034397 IMPDH1 Proteins 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N Inosine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 229940117681 Interleukin-12 Drugs 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 229940100601 Interleukin-6 Drugs 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 101710003000 ORF1/ORF2 Proteins 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- 101700030467 Pol Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N Rimantadine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims 2
- 229920002847 antisense RNA Polymers 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 101710004774 gua1 Proteins 0.000 claims 2
- 210000002443 helper T lymphocyte Anatomy 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002452 interceptive Effects 0.000 claims 2
- 101700074809 mpaF Proteins 0.000 claims 2
- 101710004466 rgy Proteins 0.000 claims 2
- 101710030364 rgy1 Proteins 0.000 claims 2
- 101710030359 rgy2 Proteins 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/044356 WO2012018325A1 (en) | 2010-08-04 | 2010-08-04 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532725A JP2013532725A (ja) | 2013-08-19 |
| JP2013532725A5 true JP2013532725A5 (me) | 2013-09-26 |
| JP5596861B2 JP5596861B2 (ja) | 2014-09-24 |
Family
ID=43640063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523129A Expired - Fee Related JP5596861B2 (ja) | 2010-08-04 | 2010-08-04 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2601188B1 (me) |
| JP (1) | JP5596861B2 (me) |
| KR (1) | KR20140045903A (me) |
| CN (1) | CN103153986B (me) |
| AU (1) | AU2010358561B2 (me) |
| BR (1) | BR112013002729A2 (me) |
| CA (1) | CA2807305A1 (me) |
| EA (1) | EA022127B1 (me) |
| IL (1) | IL224298A (me) |
| MX (1) | MX337936B (me) |
| SG (1) | SG187183A1 (me) |
| WO (1) | WO2012018325A1 (me) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| WO2011009084A2 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| EP2963034A1 (en) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Potent and selective inhibitors of hepatitis c virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2709455A4 (en) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| CN104302636B (zh) * | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | C型肝炎病毒抑制剂 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN110621652A (zh) | 2017-05-17 | 2019-12-27 | 株式会社德山 | 二氨基苯化合物的制造方法 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2020004043A1 (ja) | 2018-06-28 | 2020-01-02 | 株式会社トクヤマ | α－アジドアニリン誘導体又はα，α'－ジアジド誘導体の製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| BR0314640A (pt) * | 2002-09-20 | 2005-08-02 | Kirin Brewery | Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida |
| US7894996B2 (en) | 2005-02-28 | 2011-02-22 | The Rockefeller University | Structure of the hepatitis C NS5A protein |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010065668A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
-
2010
- 2010-08-04 CA CA2807305A patent/CA2807305A1/en not_active Abandoned
- 2010-08-04 MX MX2013001237A patent/MX337936B/es active IP Right Grant
- 2010-08-04 AU AU2010358561A patent/AU2010358561B2/en not_active Ceased
- 2010-08-04 BR BR112013002729A patent/BR112013002729A2/pt not_active IP Right Cessation
- 2010-08-04 CN CN201080069468.6A patent/CN103153986B/zh not_active Expired - Fee Related
- 2010-08-04 WO PCT/US2010/044356 patent/WO2012018325A1/en active Application Filing
- 2010-08-04 SG SG2013005558A patent/SG187183A1/en unknown
- 2010-08-04 EA EA201370017A patent/EA022127B1/ru not_active IP Right Cessation
- 2010-08-04 KR KR1020137005316A patent/KR20140045903A/ko active IP Right Grant
- 2010-08-04 JP JP2013523129A patent/JP5596861B2/ja not_active Expired - Fee Related
- 2010-08-04 EP EP10740116.8A patent/EP2601188B1/en not_active Not-in-force
-
2013
- 2013-01-17 IL IL224298A patent/IL224298A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532725A5 (me) | ||
| JP2012523415A5 (me) | ||
| JP2013510853A5 (me) | ||
| HRP20160410T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2012528161A5 (me) | ||
| JP2012512169A5 (me) | ||
| US10017499B2 (en) | Benzimidazole derivatives | |
| JP2014504643A5 (me) | ||
| JP2013521279A5 (me) | ||
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| US9060971B2 (en) | Combination pharmaceutical agents as inhibitors of HCV replication | |
| JP2012504132A5 (me) | ||
| JP2012518000A5 (me) | ||
| JP2012504632A5 (me) | ||
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| HRP20130063T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2015535853A5 (me) | ||
| JP2011511841A5 (me) | ||
| EA022127B1 (ru) | Ингибиторы вируса гепатита с | |
| JP2013514359A5 (me) | ||
| JP2012511004A5 (me) | ||
| JP2012504126A5 (me) | ||
| JP2012504129A5 (me) | ||
| JP2010508362A5 (me) | ||
| JP2011530531A5 (me) |